Status:
COMPLETED
Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Conditions:
Mucositis
Graft-versus-host Disease
Eligibility:
All Genders
Phase:
NA
Brief Summary
A comparative trial where all patients will receive daily doses of tacrolimus (TAC) until day +60 when tapering will begin, in the absence of graft-versus-host disease (GVHD), and discontinued by day ...
Detailed Description
The randomization for this comparative trial will be stratified by conditioning regimen and, for those patients enrolled on MCC-14178, by busulfan AUC level. All patients will receive daily doses of ...
Eligibility Criteria
Inclusion
- \- Patient must be going through a T cell-replete allogeneic transplant
Exclusion
- \- A contraindication to the use of tacrolimus, mycophenolate, or methotrexate
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
89 Patients enrolled
Trial Details
Trial ID
NCT00360685
Start Date
September 1 2005
End Date
January 1 2011
Last Update
May 3 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States, 33612